Computational Research Intern
Profluent
Computational Research Intern
Profluent
AI-designed bespoke proteins for genetic therapies
Profluent is the frontier AI lab for biology. Profluent builds powerful foundation models for all of life's molecules, unlocking solutions that transform medicine, agriculture, and beyond. Founded in 2022 and headquartered in Emeryville, CA, Profluent is backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures and has raised over $150M to date.
Our generative models learn the blueprint of life by modeling large-scale evolutionary data, enabling us to engineer and write biology in unprecedented ways. We are seeking a passionate Computational Research Intern to join moonshot projects at the intersection of bioinformatics and machine learning.
This is a rare opportunity to tackle open-ended scientific and engineering challenges with direct potential for high-impact publications and real-world applications in synthetic biology and protein engineering.
NOTICE TO STAFFING AND SEARCH FIRMS: Profluent does not accept unsolicited candidate submissions. We ask that agencies refrain from sending resumes to our careers inbox, hiring managers, or any Profluent employee. Any resume submitted without a signed agreement and an active search request from our Talent team will be treated as the property of Profluent, and no placement fee will be owed.
Profluent.bio designs custom proteins for genetic medicines using artificial intelligence. Its core offering is bespoke protein solutions tailored to therapeutic needs for pharmaceutical and biotech partners, helping advance treatments for genetic diseases. The product works by applying AI to optimize protein design, effectively decoding the “language of life” to create proteins that extend beyond natural or existing patented options. Partners collaborate on projects, with revenue coming from upfront fees, milestones, and royalties on successful commercialization of therapies that use their proteins. The company differentiates itself by combining AI-driven protein design with a partnership model in the gene editing and synthetic biology space, aiming to deliver more effective and precise treatments while enabling cost-efficient development. The goal is to accelerate genetic medicine by providing optimized proteins that enable new or improved therapies for genetic diseases.
Explore more opportunities at Profluent